Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Nanobiotix Announces €2.8 Million Grant to Develop NBTXR3

Published: Friday, July 05, 2013
Last Updated: Friday, July 05, 2013
Bookmark and Share
Through ETPN, Nanobiotix is driving nanomedicine in Europe and is now involved in the first nanomedicine consortium in France with the launch of NICE project.

Nanobiotix has announced that it has secured c.€9 million in funding from bpifrance (formerly OSEO) of which €2.8 million is directly attributable to the Company.

This grant, awarded through bpifrance’s Strategic Industrial Innovation (ISI) program, will accelerate the clinical and industrial development of the Company’s lead product NBTXR3 in a new indication, liver cancer (hepatocellular carcinoma).

Liver cancer is a major health problem that causes one of the greatest number of deaths each year worldwide, c.695,000 deaths per annum.

This grant supports the launch of NICE (Nano Innovation for CancEr), the first consortium of nanomedicine stakeholders in France focused on characterization and industrialization aspects.

The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France (

Consisting of five public and private partners, the NICE consortium includes partners with in depth expertise in the field of nanomedicine.

Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for advanced soft tissue sarcoma and has received authorization from the French Medicine Agency, ANSM, to start a second clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer).

NBTXR3 will benefit fully from this platform of expertise and funding received from bpifrance by being able to accelerate its clinical development.

The purpose of this project is the start of a new Phase I clinical study with NBTXR3 in patients with primary liver cancer.

In addition to Nanobiotix, the consortium includes BioAlliance Pharma, leader of the consortium which is developing Livatag®, a doxorubicin nanoparticle currently in Phase III clinical trial for treatment of primary liver cancer; CEA-Leti, the developer of cancer-detecting nanoparticles based on Leti’s Lipidots® platform; DBI, a company specialized in the production of nanomedicine pharmaceutical products and the Institut Galien Paris Sud (University Paris Sud/CNRS), which has an academic-excellence team specialized in nanoparticle research.

“Today, nanomedicine is considered as one of the major growth drivers of the global pharmaceutical industry and it is essential that the industry is structured at the local level to be competitive,” said Laurent Levy, CEO of Nanobiotix.

Levy continued, “In turn, Nanobiotix will benefit from the consortium in two ways; if the sector is structured right to be able to accelerate the development and industrialization of products, and in the development of a new indication of NBTX3 which will help patients and build shareholder value.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nanobiotix Half Year Results for the Six Months Ended 30 June 2014
Significant operational and clinical progress made.
Tuesday, September 02, 2014
Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply
Mr Otin will be responsible for the manufacturing plans to move NBTXR3 from clinical trials.
Thursday, April 17, 2014
Nanobiotix Sees Clinical Advance in STS Pilot Trial with Lead Product, NBTXR3
Market development plan outlined for earlier potential launch in 2016.
Tuesday, February 11, 2014
Nanobiotix Strengthens its Supervisory Board for the Next Stage of its Development
Anne-Marie GRAFFIN and Enno SPILLNER join the Supervisory Board.
Thursday, January 30, 2014
Nanobiotix Strengthens its Supervisory Board for the Next Stage of its Development
Anne-Marie GRAFFIN and Enno SPILLNER join the Supervisory Board.
Thursday, January 30, 2014
Nanobiotix 2013 Review: Significant Corporate and Clinical Progress
Company announces its prospective financial communications calendar for the fiscal year 2014.
Friday, January 10, 2014
NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category
NANOBIOTIX announced it has been awarded the “Young Talent” Award at the INVESTOR AWARDS 2013, referring to a newly listed company.
Friday, November 08, 2013
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with NBTXR3
Second indication for NanoXray product in Head and Neck cancer patients.
Thursday, June 13, 2013
NANOBIOTIX Announced Positive Phase I Results of NBTXR3
Company’s NBTXR3 achieves clinical milestone reaching proof-of-concept in phase I trial of STS.
Tuesday, June 04, 2013
Dr. Laurent Levy, CEO of Nanobiotix, Receives UB Entrepreneurship Award
Nanobiotix announces that its CEO and co-founder, Dr. Laurent Levy, has received the award at the Annual Inventors and Entrepreneurs Reception at the University at Buffalo (UB).
Thursday, April 04, 2013
Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference
Laurent Levy to give a Company Presentation at the 20th Annual Future Leaders in New York.
Wednesday, March 20, 2013
Nanobiotix Appoints Dr. Alain Herrera to the Supervisory Board
Former Global Oncology Head from Sanofi-Aventis joins the Nanobiotix team.
Thursday, February 14, 2013
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos